DCOY
Decoy Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.78
−1.77%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-56.0%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Lieber Jonathan I · director | A-Award | 2,000 | $0.00 |
| Sep 2, 2026 | PIERCE FREDERICK II · officer: Chief Executive Officer | A-Award | 33,455 | $0.00 |
| Sep 2, 2026 | Marschel Peter Klaus · officer: Chief Business Officer | A-Award | 3,900 | $0.00 |
| Sep 2, 2026 | Rosenblum Mark J · officer: Chief Financial Officer | A-Award | 9,682 | $0.00 |
| Sep 2, 2026 | Hibner Barbara Louise · officer: Chief Scientific Officer | A-Award | 4,216 | $0.00 |
| Sep 2, 2026 | HANISH ARNOLD C · director | A-Award | 3,000 | $0.00 |
| Sep 2, 2026 | Lammers Paul · director | A-Award | 2,000 | $0.00 |
| Sep 2, 2026 | Burleson Tess · director | A-Award | 2,000 | $0.00 |
| Sep 2, 2026 | McVicar William K. · director | A-Award | 3,000 | $0.00 |
| Sep 2, 2026 | Gauthier Patricia G. · director | A-Award | 2,000 | $0.00 |
Institutional positioning
13F filings over the trailing two quarters
New 6Increased 0Reduced 2Sold out 2
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 4,034 | Aug 13, 2026 |
| TOWER RESEARCH CAPITAL LLC (TRC) | New Position | 1,021 | May 15, 2026 |
| UBS GROUP AG | New Position | 546 | May 5, 2026 |
| Tower Research Capital LLC (TRC) | Reduced | 256 | Aug 11, 2026 |
| ADVISORY SERVICES NETWORK, LLC | New Position | 41 | May 15, 2026 |
| UBS Group AG | Reduced | 25 | Aug 13, 2026 |
| Caitong International Asset Management Co., Ltd | New Position | 2 | Aug 5, 2026 |
| MORGAN STANLEY | New Position | 1 | May 15, 2026 |
| MORGAN STANLEY | Sold Out | 0 | May 15, 2026 |
| Advisory Services Network, LLC | Sold Out | 0 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 2, 2026